Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24718253 | 1.00 | GPR119 (0.45) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL6603588 | 0.86 | HPGD (0.46) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL29152456 | 0.85 | GPR119 (0.48) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL24717734 | 0.85 | GPR119 (0.48) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL23205632 | 0.78 | GPR119 (0.52) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL26017862 | 0.78 | GPR119 (0.52) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL25133987 | 0.77 | GPR119 (0.52) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL29132229 | 0.77 | GPR119 (0.52) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL2770208 | 0.76 | GPR119 (0.61) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL25133843 | 0.76 | GPR119 (0.42) | GPR119HPGDRECQLEPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605387-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024086759-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4323352-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | GPR119 4051/4885HPGD 4244/4885RECQL 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.